Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Adding the immunotherapy spartalizumab to standard targeted therapy (dabrafenib + trametinib) boosted overall survival in patients with BRAF V600-mutant metastatic melanoma, according to a phase 3 trial. Median OS jumped from 41.6 to 61.5 months with the triple combo. The catch? The trial technically failed its primary endpoint of progression-free survival.
A phase 3 trial (COMBI-I) tested whether adding the anti-PD-1 immunotherapy spartalizumab to the standard BRAF/MEK inhibitor duo of dabrafenib and trametinib could improve outcomes in patients with BRAF V600-mutant metastatic melanoma. The rationale: pair the rapid tumor-shrinking power of targeted therapy with the durable, long-term protection of immunotherapy. Over 530 patients were enrolled and followed for a median of nearly 77 months.
The results were a mixed bag. The triple combo (sparta-DabTram) didn't hit its primary endpoint of progression-free survival — but it did show a meaningful overall survival advantage. Patients on the triple regimen lived nearly 20 months longer on average, and half were still alive at the 5-year mark.
By the Numbers:
Why it matters: While the trial's primary endpoint wasn't met — limiting formal statistical conclusions — the nearly 20-month OS gain is clinically difficult to overlook. For oncologists treating BRAF-mutant melanoma, this data adds to the growing conversation about combining targeted and immune therapies, even as the higher toxicity burden of the triple combo warrants careful patient selection.
